Upload
truongminh
View
223
Download
3
Embed Size (px)
Citation preview
Purity Testing – regulatory needs and analytical
method requirements
RPD 5th Year Anniversary 04.05.2012
Dr. Stefanie Seitz
22
www.hwi-pharma-solutions.com3
Purity Testing – regulatory needs and analytical method
requirements
› Regulatory needs
› Method development
› Stress studies
› Identification of impurities
› Validation of analytical methods
Content
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com4
Classification of impurities
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Organic impurities (process-, drug-, excipient-related)
› Starting materials
› By-products
› Intermediates
› Degradation products
› Residual solvents
› Reaction products with excipients
› Leachables from container closure systems
› Inorganic impurities
› Reagents, ligands and catalysts
› Heavy metals or other residual metals
› Inorganic salts
› Other materials (e.g., filter aids, charcoal)
www.hwi-pharma-solutions.com5
Regulatory needs – ICH Guidelines
› CPMP/ICH/2737/99: NOTE FOR GUIDANCE ON IMPURITIES TESTING: IMPURITIES IN NEW
DRUG SUBSTANCES
› CPMP/ICH/2738/99: NOTE FOR GUIDANCE ON IMPURITIES IN NEW DRUG PRODUCTS
› =>Distinct limits:
› Reporting limit (= Ph. Eur. Disregard limit)
› Identification limit
› Qualification limit
› � Action limits!
› Specification of:
› Identified impurities
› Specified unidentified impurities
› Unspecified identified impurities
› Sum of impurities
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com6
Regulatory needs – ICH Guidelines
CPMP/ICH/2737/99 & 2738/99
Presentation: Purity Testing – regulatory needs and analytical method requirements
›The CHMP/CVMP QWP has prepared a series of guidelines, which provide recommendation on the information which has to be submitted in an application file for marketing authorisation (MA). It is assumed that these guidelines represent the current knowledge on technical and scientific progress.
›In Europe, the pharmaceutical legislation makes no distinction between the quality requirements for new active substances and the quality requirements for existing generic active substances (Directives 2001/83 and 2001/82 as amended). Therefore in principle (V)ICH guidelines adopted as EU guidelines may also equally apply to new products containing existing/known active substances.
www.hwi-pharma-solutions.com7
CPMP/ICH/2737/99 - IMPURITIES IN NEW DRUG SUBSTANCES
Presentation: Purity Testing – regulatory needs and analytical method requirements
› This document is intended to provide guidance for registration applications on the content and qualification of impurities in new drug substances produced by chemical syntheses and not previously registered in a region or member state.
› It is not intended to apply to new drug substances used during the clinical research stage of development.
› The following types of drug substances are not covered in this guideline: biological/biotechnological, peptide, oligonucleotide, radiopharmaceutical, fermentation product and semi-synthetic products derived there from, herbal products, and crude products of animal or plant origin.
www.hwi-pharma-solutions.com8
CPMP/ICH/2738/99 - IMPURITIES IN NEW DRUG PRODUCTS
Presentation: Purity Testing – regulatory needs and analytical method requirements
› This guideline addresses only those impurities in new drug products classified as degradation products of the drug substance or reaction products of the drug substance with an excipient and/or immediate container closure system (collectively referred to as "degradation products" in this guideline).
› Generally, impurities present in the new drug substance need not be monitored or specified in the new drug product unless they are also degradation products (see ICH Q6A guideline on specifications).
› Impurities arising from excipients present in the new drug product or extracted or leached from the container closure system are not covered by this guideline.
www.hwi-pharma-solutions.com9
Method development for purity testing
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Performance of stress studies
› Selectivity of the used methods
› Integration of impurities
› Identification of impurities
www.hwi-pharma-solutions.com10
Stress studies in method development for purity testing
› are of fundamental importance
› for the development of "stability-indicating methods“
› for the evaluation of potential degradation products (-pathways)
› to discriminate between different types of impurities
› to determine the stability of drug substance and drug product
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com11
Stress testing (CPMP/QWP/122/02, corr.)
› Stress testing is likely to be carried out on a single batch of the active substance.
› It should include the effect of temperatures (in 10°C increments (e.g., 50°C, 60°C, etc.) above that for accelerated testing, humidity (e.g., 75 % RH or greater) where appropriate, oxidation, and photolysis on the active substance.
› The testing should also evaluate the susceptibility of the active substance to hydrolysis across a wide range of pH values when insolution or suspension.
› Photostability testing should be an integral part of stress testing. The standard conditions for photostability testing are described in the Note for Guidance on Photostability Testing of New Active Substances and Medicinal Products (CPMP/ICH/279/95)
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com12
Properties of a molecule
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com13
Performance of stress testing
Presentation: Purity Testing – regulatory needs and analytical method requirements
Hydrolysis
Oxidation
Isomerisation
Racemisation
Epimerisation
Rearrangement
Acid
Base
Oxidant
pH
Temperature
Humidity
www.hwi-pharma-solutions.com14
Performance of stress testing
› Acid: 1 % and 5% of sample solution, pH = 1, 60 °C , closed container, test
period: 2-3 days
› Base: 1 % and 5% of sample solution, pH 10, 60°C, closed container, test
period: 2-3 days
› Humidity: 25°C/75% r. h. and 40°C/75% r. h. , storage in open containers,
testing period: one week
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com15
Performance of stress testing
› Humidified samples, different temperatures (50 °C - 90°C) in closed
container, testing period: one week
› Temperature: dry, different temperatures (50 °C – 90 °C), closed containers,
testing period: one week
› Oxidation: 1% and 5% sample solution, 0,03 % H2O2, different temperatures
(30°C - 50°C), closed containers, testing period: some days
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com16
Method development
Presentation: Purity Testing – regulatory needs and analytical method requirements
0 20 40 60 80Time (min)
120min, 60°C
0 10 20 30 40 50 60 70 80 90 100Time (min)
120min, 30°C
0 10 20 30 40Time (min)
40min, 60°C
0 10 20 30 40Time (min)
40min, 30°C
www.hwi-pharma-solutions.com17
Determination of integration parameters
Presentation: Purity Testing – regulatory needs and analytical method requirements
13,2
41
14,1
97
AU
-0,010
0,000
0,010
0,020
0,030
0,040
0,050
0,060
0,070
Minutes12,00 13,00 14,00 15,00 16,00
13,2
41
14,1
83
AU
-0,010
0,000
0,010
0,020
0,030
0,040
0,050
0,060
0,070
Minutes12,00 13,00 14,00 15,00 16,00
www.hwi-pharma-solutions.com18
Determination of integration parameters
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com19
Strategies for identification
› Literature search HPLC/MS Data??
› Evaluation of suitable conditions for forced degradation
› In-situ generation of target impurity by forced degradation of the API
› (Selective) Extraction
› Purification, e.g.
› (Flash) Chromatography on silica gel
› Further purification on Sephadex®/C-18
› (Synthesis of the impurity)
› Structure elucidation (NMR, X-Ray,…)
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com20
Strategy of structure elucidation
› 1H-NMR with signal assignment
› 13C-NMR with signal assignment
› 2D-NMR-spectra for an unambiguous assignment
› Mass spectra, e.g. EI, ESI, CI, etc..
› interpretation of spectra (molecule ion & fragmentation)
› high resolution mass spectra (?)
› IR spectroscopy with assignment of characteristic absorption bands
› UV/VIS spectroscopy
› Literature search with recorded data!
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com21
Strategy of structure elucidation
› 3D structure
› X-ray diffraction (single crystals?)
› Polymorphic forms / Solid state characterisation
› X-ray diffraction (powder / single crystals?)
› Raman spectrometry
› IR
› Absolute configuration / Enantiomeric purity
› X-ray structure analysis
› Polarimetry
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com22
Validation of analytical methods
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Q2 (R1): Validation of Analytical Procedures: Text and Methodology
› Note for Guidance on Validation of Analytical Methods: Definitions
and Terminology (CPMP/ICH/381/95)
› Note for Guidance on Validation of Analytical Procedures:
Methodology (CPMP/ICH/281/95)
› „The objective of validation of an analytical procedure is to
demonstrate that it is suitable for its intended purpose.“
› „It is the responsibility of the applicant to choose the validation
procedure and protocol most suitable for their product.“
www.hwi-pharma-solutions.com23
Validation of analytical methods – ICH guideline
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com24
Validation protocol – validation report
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Introduction
› Principle of the method (assay, purity, ...)
› Reference to the analytical method
› Sample and Reference standards
› Composition
› Specification
www.hwi-pharma-solutions.com25
Validation protocol – validation report
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Validation parameter
› Specificity
› Linearity / Range
› Accuracy
› Repeatability / intermediate precision
› Detection limit / Quantitation limit
› Robustness
www.hwi-pharma-solutions.com26
Validation protocol – validation report
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Summary, table
› Statistic evaluation of the data
› Evaluation of the results with repect to the acceptance criteria
› Deviations
› Chromatograms
www.hwi-pharma-solutions.com27
Validation - Specificity
› Proof of the identity of the drug substance by comparison with a reference standard
› Retention time and spectrum (UV, MS)
› Co-injection of drug substance and reference standard
› Acceptance criteria
› No interference with Drug substance
› Proof of peak purity
› Chromatograms of
› Solvent
› Reference standard
› Drug substance
› Drug substance + Reference standard
› Matrix
› Drug product
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com28
Validation - Specificity
› Chromatograms of
› Identified impurities, individually
› Drug product, spiked with impurity
› Stress testing (acidic, basic, oxidative, reductive, thermal)
› Reference samples of „aged“ batches
› Reference solution at specification limit and reporting level
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com29
Validation - Linearity
› „A linear relationship should be evaluated across the range of the analytical procedure.“
› „The correlation coefficient, y-intercept, slope of the regression line and residual sum of squares should be submitted. A plot of the data should be included.“
› Minimum specified ranges to be considered
› purity: reporting level - 120 % of specification
› Purity 100 % method: reporting level – 120 % of the assay specification
› Validation is performed using the drug substance as well as identified impurities
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com30
Validation - Linearity
Presentation: Purity Testing – regulatory needs and analytical method requirements
-10000000
0
10000000
20000000
30000000
40000000
0.1 0.2 0.3 0.4
Area
Gesamtparabene [mg/mL]
Legende
MeßwerteRegression
Konfidenzintervall
y = 82967451,4447x - 11072,1573
Konf(0)=[-75076,6173 ; 52932,3026]
-60000
-40000
-20000
0
20000
40000
60000
0.1 0.2 0.3 0.4
Are
a
Gesamtparabene [mg/mL]
www.hwi-pharma-solutions.com31
Validation - Linearity
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Evaluation of the residuals
www.hwi-pharma-solutions.com32
Validation - Range
Presentation: Purity Testing – regulatory needs and analytical method requirements
› „The specified range is normally derived from the linearity studies and
depends on the intended application of the procedure.“
› „It is established by confirming that the analytical procedure provides
an acceptable degree of linearity, accuracy and precision when
applied to samples containing amounts of analyte within or at the
extremes of the specified range of the analytical procedure.“
www.hwi-pharma-solutions.com33
Validation - Accuracy
Presentation: Purity Testing – regulatory needs and analytical method requirements
› „application of the analytical procedure to synthetic mixtures of the
product components to which known quantities of the substance to
be analysed have been added“
› „in cases where it is impossible to obtain samples of all product
components, it may be acceptable to add known quantities of the
analyte to the product or to compare the results from a second, well
characterised procedure, the accuracy of which is stated and/or
defined (independent procedure)“
www.hwi-pharma-solutions.com34
Validation - Accuracy
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Proof of accuracy by determination of recovery
› Impurity is spiked to drug product: concentration of the impurity
at n = 3 levels (reporting level, specification, 200 % of the
specification, each n = 3 determinations)
› accuracy for unknown impurities on the drug substance or
identified impurity
› Acceptance criteria
› recovery = 90 - 110 %
› COV < 10 %
www.hwi-pharma-solutions.com35
Validation - Precision
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com36
Validation - Repeatability
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Precision with minimum of n = 6
› Drug product, if impurities are present
› Reference samples of „aged“ batches
› Stressed samples
› Acceptance criteria: COV < 5 - 10 %
www.hwi-pharma-solutions.com37
Validation – Intermediate precision
Presentation: Purity Testing – regulatory needs and analytical method requirements
› according to the repeatability
› Acceptance criteria:
› precision: COV < 5 - 10 %
› if necessary, compare the mean values: deviation of the mean values with respect to the higher value of <10%
www.hwi-pharma-solutions.com38
Validation – Limit of quantitation (LOQ)
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Required for quantitative determination of impurities
› LOQ <= reporting level
› Options
› based on the signal-to-noise ratio S / N ≥ 10:1
› based on visual analysis
› based on the calculation of standard deviation / slope
› based on the standard deviation of the blank sample
› based on a calibration curve
› Presentation of the relevant chromatograms
www.hwi-pharma-solutions.com39
Validation – Limit of determination (LOD)
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Required for limit tests of impurities
› LOD <= ½ reporting level
› Options
› based on the signal-to-noise ratio S / N ≥ 3:1
› based on visual analysis
› based on the calculation of standard deviation / slope
› based on the standard deviation of the blank sample
› based on a calibration curve
› Presentation of the relevant chromatograms
www.hwi-pharma-solutions.com40
Validation – Robustness
Presentation: Purity Testing – regulatory needs and analytical method requirements
› Sample preparation
› e.g. extraction of a sample
› Extraction of impurities_ validation on drug substance and impurity reference standards
› Behaviour of unknown impurities
› amount of substance
› Amount of extractant
› Extraction conditions, e.g. shaking, stirring, mixing, extraction time, extraction temperature
www.hwi-pharma-solutions.com41
Validation – Robustness
Presentation: Purity Testing – regulatory needs and analytical method requirements
› HPLC / GC method:
› Colum, e.g. batch, different suppliers
› Pre-columns
› Gradient or temperature program
› Flow rate
› pH-value and composition of solvents
› Detection wavelength
› Stability of Reference standard
› Stability of sample
HWI ANALYTIK GmbH
Rheinzaberner Str. 8
76761 Rülzheim
Tel: +49 7272 7767-0
Fax: +49 7272 7767-11
E-mail: [email protected]
Web: www.hwi-pharma-solutions.com
42
thank you very much for your attention!
www.hwi-pharma-solutions.com43
Glossary I› Impurity: Any component of the drug substance/product that is not the chemical
entity defined as the drug substance. Any component of the new drug product that is not the drug substance or an excipient in the drug product
› Reporting Threshold: A limit above which an impurity should be reported. Reporting threshold is the same as reporting level in Q2B
› Identification Threshold: A limit above which a impurity should be identified
› Degradation Product: An impurity resulting from a chemical change in the drug substance/drug product brought about during manufacture and/or storage of the drug substance/drug product by the effect of, for example, light, temperature, pH, water, or by reaction with an excipient and/or the immediate container closure system
› Identified Impurity: A impurity for which a structural characterisation has been achieved
› Unidentified (Specified) Impurity: A impurity for which a structural characterisation has not been achieved and that is defined solely by qualitative analytical properties (e.g., chromatographic retention time).
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com44
Glossary II› Unspecified Impurity: A degradation product that is limited by a general acceptance
criterion, but not individually listed with its own specific acceptance criterion, in the specification
› Specified Impurity: A impurity that is individually listed and limited with a specific acceptance criterion in the specification. A specified degradation product can be either identified or unidentified
› Qualification: The process of acquiring and evaluating data that establishes the biological safety of an individual impurity or a given degradation profile at the level(s) specified
› Qualification Threshold: A limit above (>) which a impurity should be qualified.
› Potential Impurity: An impurity that theoretically can arise during manufacture orstorage. It may or may not actually appear in the new drug substance/drug product
› Other detectable Impurity: Specific EP category
Presentation: Purity Testing – regulatory needs and analytical method requirements
www.hwi-pharma-solutions.com45
Literature – regulatory needs
Presentation: Purity Testing – regulatory needs and analytical method requirements
Note for Guidance on impurities testing: Impurities in new drug productsCPMP/ICH/2738/99
Note for Guidance on impurities testing: Impurities in new drug substancesCPMP/ICH/2737/99
Guideline on control of impurities in pharmacopeial substancesCPMP/QWP/1529/04
Note for Guidance specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances
CPMP/ICH/367/96
Guideline on chemistry of the new active substanceCPMP/QWP/130/96 Rev 1
Note for Guidance on summary of requirements foractive substances in the quality part of the dossier
CHMP/QWP/297/97Rev 1 corr
www.hwi-pharma-solutions.com46
Literature - Validation
Presentation: Purity Testing – regulatory needs and analytical method requirements
Note for Guidance on validation of analytical procedures: Definitions and terminology
CPMP/ICH/381/95
Note for Guidance on validation of analytical procedures: Methodology CPMP/ICH/281/95